Star Equity Holdings, Inc. (STRR)
USD 2.0
(-0.99%)
USD 2.0
(-0.99%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 86.97 Million USD | 18.65% |
| 2022 | 73.3 Million USD | 7.71% |
| 2021 | 68.05 Million USD | -22.92% |
| 2020 | 88.29 Million USD | -2.5% |
| 2019 | 90.56 Million USD | 78.99% |
| 2018 | 50.59 Million USD | -24.15% |
| 2017 | 66.7 Million USD | -37.23% |
| 2016 | 106.26 Million USD | 65.74% |
| 2015 | 64.11 Million USD | 53.01% |
| 2014 | 41.9 Million USD | 1.09% |
| 2013 | 41.45 Million USD | -7.7% |
| 2012 | 44.9 Million USD | -10.23% |
| 2011 | 50.02 Million USD | -4.57% |
| 2010 | 52.42 Million USD | -10.68% |
| 2009 | 58.68 Million USD | -4.1% |
| 2008 | 61.19 Million USD | -11.33% |
| 2007 | 69.01 Million USD | -0.38% |
| 2006 | 69.27 Million USD | -7.02% |
| 2005 | 74.5 Million USD | -13.39% |
| 2004 | 86.02 Million USD | 144.67% |
| 2003 | 35.15 Million USD | 6.16% |
| 2002 | 33.11 Million USD | 0.0% |
| 2000 | 23.05 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 71.64 Million USD | -17.62% |
| 2024 Q2 | 80.86 Million USD | 12.86% |
| 2023 Q4 | 86.97 Million USD | 20.36% |
| 2023 FY | 86.97 Million USD | 18.65% |
| 2023 Q1 | 69.5 Million USD | -5.19% |
| 2023 Q3 | 72.26 Million USD | -2.98% |
| 2023 Q2 | 74.47 Million USD | 7.16% |
| 2022 Q4 | 73.3 Million USD | -4.77% |
| 2022 Q3 | 76.97 Million USD | -5.72% |
| 2022 Q1 | 81.19 Million USD | 19.31% |
| 2022 FY | 73.3 Million USD | 7.71% |
| 2022 Q2 | 81.64 Million USD | 0.56% |
| 2021 FY | 68.05 Million USD | -22.92% |
| 2021 Q2 | 75.38 Million USD | -7.38% |
| 2021 Q3 | 74.88 Million USD | -0.66% |
| 2021 Q4 | 68.05 Million USD | -9.13% |
| 2021 Q1 | 81.39 Million USD | -7.82% |
| 2020 Q1 | 83.8 Million USD | -7.46% |
| 2020 Q4 | 88.29 Million USD | 2.72% |
| 2020 Q3 | 85.95 Million USD | -3.72% |
| 2020 Q2 | 89.27 Million USD | 6.53% |
| 2020 FY | 88.29 Million USD | -2.5% |
| 2019 FY | 90.56 Million USD | 78.99% |
| 2019 Q1 | 54.59 Million USD | 7.9% |
| 2019 Q2 | 57.85 Million USD | 5.97% |
| 2019 Q3 | 91.36 Million USD | 57.92% |
| 2019 Q4 | 90.56 Million USD | -0.88% |
| 2018 Q3 | 55.18 Million USD | -4.64% |
| 2018 Q1 | 59.96 Million USD | -10.11% |
| 2018 Q4 | 50.59 Million USD | -8.33% |
| 2018 Q2 | 57.87 Million USD | -3.48% |
| 2018 FY | 50.59 Million USD | -24.15% |
| 2017 Q3 | 87.61 Million USD | -10.86% |
| 2017 FY | 66.7 Million USD | -37.23% |
| 2017 Q2 | 98.29 Million USD | -4.41% |
| 2017 Q4 | 66.7 Million USD | -23.87% |
| 2017 Q1 | 102.82 Million USD | -3.23% |
| 2016 Q3 | 107.08 Million USD | -3.12% |
| 2016 FY | 106.26 Million USD | 65.74% |
| 2016 Q4 | 106.26 Million USD | -0.77% |
| 2016 Q2 | 110.53 Million USD | -5.06% |
| 2016 Q1 | 116.43 Million USD | 81.61% |
| 2015 Q3 | 65.55 Million USD | 41.22% |
| 2015 Q2 | 46.42 Million USD | 3.46% |
| 2015 FY | 64.11 Million USD | 53.01% |
| 2015 Q1 | 44.87 Million USD | 7.09% |
| 2015 Q4 | 64.11 Million USD | -2.2% |
| 2014 Q2 | 40.77 Million USD | 0.53% |
| 2014 FY | 41.9 Million USD | 1.09% |
| 2014 Q4 | 41.9 Million USD | -0.63% |
| 2014 Q3 | 42.16 Million USD | 3.42% |
| 2014 Q1 | 40.55 Million USD | -2.15% |
| 2013 Q1 | 42.74 Million USD | -4.82% |
| 2013 FY | 41.45 Million USD | -7.7% |
| 2013 Q4 | 41.45 Million USD | -1.27% |
| 2013 Q3 | 41.98 Million USD | 6.78% |
| 2013 Q2 | 39.31 Million USD | -8.01% |
| 2012 FY | 44.9 Million USD | -10.23% |
| 2012 Q1 | 49.19 Million USD | -1.66% |
| 2012 Q4 | 44.9 Million USD | -4.85% |
| 2012 Q3 | 47.19 Million USD | -2.06% |
| 2012 Q2 | 48.19 Million USD | -2.04% |
| 2011 Q2 | 52.78 Million USD | -0.36% |
| 2011 Q4 | 50.02 Million USD | -4.17% |
| 2011 Q1 | 52.97 Million USD | 1.06% |
| 2011 FY | 50.02 Million USD | -4.57% |
| 2011 Q3 | 52.2 Million USD | -1.1% |
| 2010 Q2 | 54.86 Million USD | -5.55% |
| 2010 Q4 | 52.42 Million USD | -0.45% |
| 2010 FY | 52.42 Million USD | -10.68% |
| 2010 Q1 | 58.08 Million USD | -1.03% |
| 2010 Q3 | 52.65 Million USD | -4.02% |
| 2009 Q3 | 60.17 Million USD | -3.13% |
| 2009 Q4 | 58.68 Million USD | -2.46% |
| 2009 FY | 58.68 Million USD | -4.1% |
| 2009 Q2 | 62.11 Million USD | 2.8% |
| 2009 Q1 | 60.42 Million USD | -1.26% |
| 2008 Q1 | 66.72 Million USD | -3.32% |
| 2008 Q4 | 61.19 Million USD | -5.39% |
| 2008 Q3 | 64.67 Million USD | -1.38% |
| 2008 FY | 61.19 Million USD | -11.33% |
| 2008 Q2 | 65.58 Million USD | -1.72% |
| 2007 FY | 69.01 Million USD | -0.38% |
| 2007 Q4 | 69.01 Million USD | -0.7% |
| 2007 Q3 | 69.5 Million USD | 0.09% |
| 2007 Q2 | 69.43 Million USD | 2.0% |
| 2007 Q1 | 68.07 Million USD | -1.73% |
| 2006 FY | 69.27 Million USD | -7.02% |
| 2006 Q2 | 70.89 Million USD | -1.0% |
| 2006 Q3 | 68.53 Million USD | -3.33% |
| 2006 Q1 | 71.61 Million USD | -3.88% |
| 2006 Q4 | 69.27 Million USD | 1.09% |
| 2005 Q2 | 80.62 Million USD | -4.42% |
| 2005 FY | 74.5 Million USD | -13.39% |
| 2005 Q1 | 84.35 Million USD | -1.94% |
| 2005 Q3 | 76.81 Million USD | -4.73% |
| 2005 Q4 | 74.5 Million USD | -3.0% |
| 2004 Q1 | 38.01 Million USD | 0.0% |
| 2004 Q2 | 88.14 Million USD | 131.9% |
| 2004 Q3 | 86.12 Million USD | -2.3% |
| 2004 FY | 86.02 Million USD | 144.67% |
| 2004 Q4 | 86.02 Million USD | -0.11% |
| 2003 FY | 35.15 Million USD | 6.16% |
| 2002 FY | 33.11 Million USD | 0.0% |
| 2000 FY | 23.05 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aspira Women's Health Inc. | 6.26 Million USD | -1288.917% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -957.878% |
| Intelligent Bio Solutions Inc. | 13.77 Million USD | -531.213% |
| Standard BioTools Inc. | 323.06 Million USD | 73.079% |
| Inotiv, Inc. | 856.53 Million USD | 89.846% |
| Prenetics Global Limited | 254.17 Million USD | 65.781% |
| Neuronetics, Inc. | 115.83 Million USD | 24.913% |
| Castle Biosciences, Inc. | 477.81 Million USD | 81.797% |
| Psychemedics Corporation | 13.27 Million USD | -555.418% |
| RadNet, Inc. | 2.88 Billion USD | 96.987% |
| Exact Sciences Corporation | 6.47 Billion USD | 98.656% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 97.332% |
| iSpecimen Inc. | 15.81 Million USD | -449.802% |
| OpGen, Inc. | 1.88 Million USD | -4520.688% |
| Exagen Inc. | 56.94 Million USD | -52.736% |
| Bionano Genomics, Inc. | 214.4 Million USD | 59.435% |
| CareDx, Inc | 484.61 Million USD | 82.053% |
| Check-Cap Ltd. | 25.01 Million USD | -247.66% |
| Twist Bioscience Corporation | 776.4 Million USD | 88.798% |
| Guardant Health, Inc. | 1.78 Billion USD | 95.131% |
| Biodesix, Inc. | 99.09 Million USD | 12.233% |
| BioNexus Gene Lab Corp. | 11.39 Million USD | -662.944% |
| Precipio, Inc. | 18.1 Million USD | -380.493% |
| Natera, Inc. | 1.45 Billion USD | 94.031% |
| Fulgent Genetics, Inc. | 1.27 Billion USD | 93.168% |
| Sera Prognostics, Inc. | 95.44 Million USD | 8.871% |
| 23andMe Holding Co. | 395.16 Million USD | 77.991% |
| OPKO Health, Inc. | 2.01 Billion USD | 95.677% |
| Personalis, Inc. | 225.09 Million USD | 61.362% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 55.941% |
| Applied DNA Sciences, Inc. | 13.65 Million USD | -537.099% |
| T2 Biosystems, Inc. | 34.79 Million USD | -149.947% |
| Neogen Corporation | 4.58 Billion USD | 98.103% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 92.744% |
| ICON Public Limited Company | 16.98 Billion USD | 99.488% |
| NeoGenomics, Inc. | 1.68 Billion USD | 94.827% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 0.0% |
| MDxHealth SA | 129.13 Million USD | 32.647% |
| Prenetics Global Limited | 254.17 Million USD | 65.781% |
| Illumina, Inc. | 10.11 Billion USD | 99.14% |
| DarioHealth Corp. | 96.38 Million USD | 9.768% |
| ENDRA Life Sciences Inc. | 6.75 Million USD | -1187.713% |
| Medpace Holdings, Inc. | 1.65 Billion USD | 94.751% |
| Mainz Biomed B.V. | 15.4 Million USD | -464.435% |
| Trinity Biotech plc | 59.43 Million USD | -46.335% |
| Sotera Health Company | 3.13 Billion USD | 97.222% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -957.878% |